Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 3/20 | 0.41 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848654 | 0.83 | CTSL (0.52) | ALDH1A1MAPTCHRM2CHRM4CHRM1 | |
| SCHEMBL5849932 | 0.82 | DRD2 (0.48) | ALDH1A1MAPTCASP1CASP3CASP7 | |
| SCHEMBL5850300 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTCASP1CASP7CHRM2 | |
| SCHEMBL5850357 | 0.79 | CHRM2 (0.45) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5848547 | 0.78 | CHRM2 (0.46) | ALDH1A1MAPTCHRM2CHRM4CHRM1 | |
| SCHEMBL5849886 | 0.77 | ALDH1A1 (0.45) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5850047 | 0.76 | CTSK (0.53) | CAPN1 | |
| SCHEMBL5848336 | 0.75 | CTSK (0.47) | ALDH1A1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5850493 | 0.75 | CTSS (0.50) | MAPTHDAC1HDAC8HDAC6MAPK1 | |
| SCHEMBL7253433 | 0.75 | CHRM2 (0.54) | ALDH1A1MAPTCASP1CASP7CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | claimed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | ALDH1A1 1884/4885MAPT 1540/4885CASP1 8/4885 |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | BACE1, BACE2, CBS | ALDH1A1 3625/4885MAPT 955/4885CASP1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.